ライフサイエンスコーパス: recurrence

1 2 cases unclear location; 7 patients with >1 recurrence).

2 patient's present disease status relative to recurrence.

3 tribute to therapeutic resistance and cancer recurrence.

4 ho were followed to 6 months, 4 (4%) had CDI recurrence.

5 8 of 66 (12.1%) patients had exclusive local recurrence.

6 cer stem cells and to prevent ovarian cancer recurrence.

7 ommend a "wait-and-watch" approach for tumor recurrence.

8 hiscence), abdominal eventration, and hernia recurrence.

9 e to treatment and in detecting postsurgical recurrence.

10 ing LT) for HCC are at a high risk for tumor recurrence.

11 t cancer is common and increases the risk of recurrence.

12 y the major reason for treatment failure and recurrence.

13 ring tumor regression, residual disease, and recurrence.

14 tection of tumors and can reduce the risk of recurrence.

15 e means supporting early detection of tumour recurrence.

16 tric cell division and responsible for tumor recurrence.

17 Six patients (23%) developed disease recurrence.

18 less suitable if there is a higher risk for recurrence.

19 independent risk factor in predicting early recurrence.

20 there were 42 (8%) patients with documented recurrence.

21 odel, was the time to the first pericarditis recurrence.

22 ons, and is associated with a 40-80% risk of recurrence.

23 etastasis, drug resistance and high rates of recurrence.

24 eatment delay for patients with early glioma recurrence.

25 s associated with an increased risk of early recurrence.

26 ility to identify lesions with potential for recurrence.

27 eningioma as a marker that can predict tumor recurrence.

28 for first recurrence, and FMT for subsequent recurrence.

29 predict metastatic rather than loco-regional recurrence.

30 hickness and >=0.5 mm in LBD indicated local recurrence.

31 which leads to treatment failure and symptom recurrence.

32 no association between dual therapy and CDI recurrence.

33 o prevent C. difficile infection and disease recurrence.

34 hylation status remained prognostic at tumor recurrence.

35 (3.01, 1.69-5.39) were predictors of hernia recurrence.

36 mouse resection model with no sign of tumour recurrence.

37 of recurrence, and 47% were at high risk of recurrence.

38 cipants without documented atrial arrhythmia recurrences.

39 rates, survival probabilities and cumulative recurrences.

40 The cumulative probability of recurrence 1, 2, 3, 4, 5, and 6 years after the initial

41 0.061), distant (9 vs 3, P = 0.135) and any recurrence (11 vs 7, P = 0.525).

42 atic cancer (17 months) and those with local recurrence (16 months).

43 434 (10%) of 4480 women had a breast cancer recurrence (280 [9%] POAI; 154 [10%] control), hazard ra

44 Unilateral PAE was associated with higher recurrence (42% vs 21%; P = .04).

45 The majority of recurrences (74%) occurred after 3 years, and a signific

46 +/- 5.3 vs. 2.2 +/- 3.7, P = 0.02, for local recurrence; 9.8 +/- 9.7 vs. 2.3 +/- 2.6, P < 0.001, for

47 he median OS was 16 months from diagnosis of recurrence (95% CI: 11 months, 22 months) and 9 months f

48 25% lower risk of post-liver transplant HCC recurrence (95CI 0.57-0.99).

49 to drive tumour initiation, maintenance and recurrence across individual subgroups and subtypes.

50 emotherapy was significantly associated with recurrence (adjHR, 1.79; 95% CI, 1.20 to 2.67; P < .01)

51 ALN status was not associated with tumor recurrence [adjusted hazard ratio (HR) 1.02, 95% confide

52 associated with overall recurrence, multiple recurrence, advanced recurrence, proximal recurrence, an

53 monitoring (ICM) in the prevention of stroke recurrence after a cryptogenic ischemic stroke or transi

54 this study was to identify risk factors for recurrence after accessory pathway (AP) ablation.

55 linical awareness of increased risk of local recurrence after anastomotic leakage throughout the foll

56 , is a modifiable risk factor for colorectal recurrence after curative resection.

57 dy was to characterize the patterns of first recurrence after curative-intent resection for pancreati

58 ted to metastatic spread of disease or tumor recurrence after initial treatment.

59 e aim of this study was to investigate tumor recurrence after liver transplantation for hepatocellula

60 Recurrence after metronidazole treatment is high.

61 requirement of advanced surgery, and pelvic recurrence after regrowth treatment.

62 This system also prevents tumor recurrence after surgical resection and results in 100%

63 Long-term follow-up data on recurrence after surgical resection for IPMN are current

64 ults on the role of margin status in risk of recurrence after surgical resection.

65 cal features of the parenchymal margin) with recurrence after surgical resection.

66 Local recurrence after transarterial embolization (TAE) of hep

67 the circulating factor or as a predictor of recurrence after transplantation remains controversial.

68 When hepatic recurrences after ALPPS was amenable to surgical/ablativ

69 ently associated with an increased hazard of recurrence (aHR, 1.88; 95% CI, 1.04 to 3.25).

70 The lowest risk of recurrence among those with precipitants occurred with p

71 ation and distant recurrence or death before recurrence), an exploratory endpoint in Short-HER.

72 35 prostate cancer patients with biochemical recurrence and a PSA level of less than 1 ng/mL.

73 stering of MSF, (ii) six of seven cases with recurrence and all distant metastases were of MSFs, (iii

74 after cancer diagnosis had increased risk of recurrence and cancer-specific death.

75 es were the competing risks incidence of CRC recurrence and CRC-specific death.

76 Subsequent PDT further reduced tumor recurrence and extended animal survival significantly.

77 resistance are major contributors to cancer recurrence and failed GBM therapy.

78 ix polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05).

79 imal risk of immunologic rejection, herpetic recurrence and graft failure.

80 fication of MPBC-HGT1 enabling prediction of recurrence and guide therapeutic management for individu

81 Timely detection of HCC recurrence and its clonality is required to implement sa

82 lymph-node involvement were associated with recurrence and lower disease-free survival.

83 on cutaneous squamous cell carcinoma (CSCC) recurrence and metastasis.

84 to potentiate immunotherapy and reduce tumor recurrence and metastasis.

85 pids have recently emerged as a biomarker of recurrence and mortality after myocardial infarction (MI

86 we demonstrated HPV genotypic differences in recurrence and patient outcomes in cervical and head and

87 nd extrahepatic bile duct with potential for recurrence and persistent local growth.

88 P1) is predictive of colorectal cancer (CRC) recurrence and poor patient survival.

89 al fibrillation (AF), but many experience AF recurrence and require repeat ablation procedures.

90 vival and expansion, thus underlying disease recurrence and resistance to conventional therapies, and

91 Recurrence and survival were indexed at 6 months after e

92 he adjusted estimates of the burden of first recurrences and in-hospital deaths did not change signif

93 ence), 4 of 16 had new lesions only (25% PET recurrence), and 2 had no disease on post-SLND PET.

94 cancer, 58 women with previous treatment or recurrence, and 14 women from small racial groups (white

95 nned for primary staging, 67 for biochemical recurrence, and 23 for metastatic castration-resistant P

96 vic lymph nodes were the most common site of recurrence, and 28% of patients had (11)C-choline-positi

97 children (1.0%) experienced on-treatment VTE recurrence, and 3 of 203 (1.5%) experienced major bleedi

98 histology, 53% were at intermediate risk of recurrence, and 47% were at high risk of recurrence.

99 improvement (>35%) and recovery (>=50%), AF recurrence, and AF ablation were determined.

100 le recurrence, advanced recurrence, proximal recurrence, and distal adenoma recurrence with odds rati

101 omycin for severe CDI, fidaxomicin for first recurrence, and FMT for subsequent recurrence.

102 than 97% rate of 8-year freedom from distant recurrence, and improvements with exemestane plus OFS ra

103 operative complications, long-term function, recurrence, and survival.

104 litate early diagnosis of cancer and disease recurrence, and which could potentially inform on timing

105 shift towards the mesenchymal phenotype upon recurrence are generally associated with treatment resis

106 is, the genomic events that drive metastatic recurrence are poorly understood.

107 ) in the rilonacept group had a pericarditis recurrence, as compared with 23 of 31 patients (74%) in

108 e specific prognosis, the kinetics of cancer recurrence, as well as the limited data on the effects o

109 I trial were disease-free survival and local recurrence at 3-year follow-up, respectively, and second

110 with the proportion free from breast cancer recurrence at 5 years of 91.0% (95% CI 89.9-92.0) for pa

111 Of 15 recurrences at SSIS's, 11 required surgical treatment (r

112 state cancer (PCa) patients with biochemical recurrence (BCR) is well established.

113 imary staging (n = 93/388, 24%), biochemical recurrence (BCR) localization (n = 225/388, 58%), or res

114 F-DCFPyL PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC).

115 CDR) of (18)F-rhPSMA-7 PET/CT in biochemical recurrence (BCR) of prostate cancer (PCa) after radical

116 Margins up to 0.5 mm offers a local recurrence benefit but does not confer survival benefit.

117 ical site occurrence, eventration, or hernia recurrence between groups.

118 Primary end points included VTE recurrence, bleeding events, and mortality at 6 and 12 m

119 reated with bone-modifying agents to prevent recurrence, but could still receive these agents to prev

120 The risk ratio for recurrence by week 24 (also calculated with multiple imp

121 as 60-day all-cause mortality and/or 60-day recurrence compared with patients treated with daptomyci

122 to LA connections reduced atrial arrhythmia recurrences compared with standard pulmonary vein isolat

123 The extent to which influenza recurrence depends upon waning immunity from prior-infec

124 uding biochemical failure, local or regional recurrence, distant metastasis, or death from any cause,

125 ently associated with a lower risk of stroke recurrence during follow-up (HR = 0.32, 95% CI = 0.11-0.

126 therapy with a high acute success rate, but recurrence during follow-up remains a concern.

127 clusion: (11)C-choline PET/CT can detect PCa recurrence even among patients with low PSA levels when

128 been associated with a significant risk for recurrence, extraocular spread, and systemic metastases.

129 tween margins and overall survival and local recurrence free survival were explored using Kaplan-Meie

130 Primary outcome was recurrence free survival.

131 Overall, cancer-specific (CSS), and recurrence-free (RFS) survivals were analyzed along with

132 Importantly, recurrence-free and overall survival of colorectal cance

133 d significant differences in 10-year distant recurrence-free interval (DRFI) (94.1% vs. 85.0%, P < 0.

134 s a significant prognostic factor for better recurrence-free survival (P < 0.001), with a median time

135 vival (Relative Risk: 2.129, p < 0.0001) and recurrence-free survival (Relative Risk: 1.299, p < 0.00

136 The primary outcome was neck node recurrence-free survival (RFS) at 2 years.

137 AJCC 7 Stage was not predictive of recurrence-free survival (RFS) or overall survival (OS).

138 ths, 1- and 5-year overall survival (OS) and recurrence-free survival (RFS) were 82%, 57%, and 77%, 5

139 ogic characteristics, overall survival (OS), recurrence-free survival (RFS), and HCC recurrence (HCC-

140 m outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-specific mortali

141 Recurrence-free survival (RFS), the primary outcome meas

142 The primary end point was recurrence-free survival (RFS).

143 fety and tolerability (primary outcomes) and recurrence-free survival (secondary outcome).

144 The primary endpoint was recurrence-free survival by investigator assessment, and

145 he NAFLD-HCC patients had a trend for higher recurrence-free survival rates compared to HBV and HCV-H

146 ated HCC patients had longer overall but not recurrence-free survival rates compared to patients with

147 olumab plus ipilimumab group, whereas median recurrence-free survival was 12.4 months (95% CI 5.3-33.

148 Median abdominal recurrence-free survival was 4.5 years (95% CI 3.9 to no

149 ow-up of 28.4 months (IQR 17.7-36.8), median recurrence-free survival was not reached in the nivoluma

150 d all distant metastases were of MSFs, (iii) recurrence-free survival was worse in MSF than in the ST

151 The primary endpoint was recurrence-free survival, analysed in the per-protocol p

152 with reduced prostate-specific antigen (PSA) recurrence-free survival.

153 essive tumor phenotypes and is predictive of recurrence-free survival.

154 d from those that are suspected, symptomatic recurrence from radiographic recurrence (that is, with r

155 age III colon cancer into high- and low-risk recurrence groups, and poor and good prognosis groups di

156 in two clinical cohorts, finding women with recurrence have significantly higher pre-treatment level

157 Baseline PSA was inversely related with recurrence (hazard ratio, 0.9 per nanograms per millilit

158 OS), recurrence-free survival (RFS), and HCC recurrence (HCC-R) were compared between patients within

159 ssion analysis for post-liver transplant HCC recurrence highlighted that even after accounting for et

160 breast cancer does not increase the risk of recurrence; however, very limited data are available in

161 ions persisted between TNM N-status and both recurrence (HR 1.58, CI 1.21-2.06) and CRC-specific deat

162 atients with first graft loss due to disease recurrence (HR: 0.31; P = .002, HR 0.32; P = .003, respe

163 nefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49-0.59, P = 0.0079-0.0245).

164 We sought to determine the rates of hernia recurrence(HR) and surgical site occurrences(SSOs) in a

165 eactants should raise concerns about amyloid recurrence in allograft.

166 rade IPMN was identified as risk factors for recurrence in both uni- and multivariate analysis (adjus

167 Knowledge about patterns of recurrence in different patient populations could offer

168 Missed nodal disease correlates with recurrence in early stage NSCLC.

169 RNA and OPN protein expression as markers of recurrence in estrogen receptor- positive (ER+) breast c

170 he margin were significantly correlated with recurrence in margin-positive patients.

171 T-alt) have been linked to increased risk of recurrence in meningiomas, whereas the association to mo

172 margin was not significantly associated with recurrence in our cohort, the size and grade of the dysp

173 irals (DAA) on the risk of death and tumoral recurrence in patients with hepatitis C virus (HCV) and

174 hmia recurrences in the standard group and 1 recurrence in the CS-LA connection elimination group (46

175 patients with high-grade disease may have a recurrence in the form of low-grade disease after immuno

176 t possible to modify seamlessly due to their recurrence in the genome or essentiality for cell functi

177 vival analysis revealed an increased risk of recurrence in the minimally invasive group in propensity

178 he limited data regarding the risk of cancer recurrence in transplant recipients, the goal of the AST

179 to simulate patterns of local versus distant recurrences in a non-small cell lung cancer (NSCLC) popu

180 5%) recurrences in the open RH and 51 (9.1%) recurrences in the minimally invasive group (P = .43).

181 There were 19 (7.5%) recurrences in the open RH and 51 (9.1%) recurrences in

182 70+/-22 days, there were 7 atrial arrhythmia recurrences in the standard group and 1 recurrence in th

183 e needed to ensure long-term freedom from AF recurrences in these high-risk patients.

184 ent to the date of first evidence of disease recurrence, including biochemical failure, local or regi

185 sms by which the Western diet promotes tumor recurrence, including changes in the microbiome, in mice

186 ancreatectomies, and 10 resections for tumor recurrences, including 121 multivisceral resections and

187 past six millennia, indicating sub-millennia recurrence intervals over this time period.

188 Once CRIM is achieved, recurrence is common and mandates continued endoscopic f

189 and creates an environment in which disease recurrence is likely.

190 er irradiation, tumors are eradicated and no recurrence is observed.

191 we could better define the factors affecting recurrence levels and estimate the inversion rate across

192 and mortality rates (iii) local and distant recurrence (LR), (iv) disease free survival (DFS), (v) o

193 noscopy was strongly associated with overall recurrence, multiple recurrence, advanced recurrence, pr

194 st-treatment time points, and none developed recurrence (NPV, 100%; 95% CI, 96% to 100%).

195 reoperative predictors of non transplantable recurrence (NTR) to improve patient selection for upfron

196 Recurrence occurred in 3.3% (n = 18) of the total cohort

197 survival (P < 0.001), with a median time to recurrence of 41.2 versus 5.5 months in nonresponders.

198 d a hazard ratio (HR) for high- vs. low-risk recurrence of 8.976 (95% confidence interval (CI), 2.824

199 e primary end point was the first documented recurrence of any atrial tachyarrhythmia (atrial fibrill

200 There was no recurrence of bleeding after reintervention.

201 ion therapy resulted in a lower incidence of recurrence of cellulitis than conservative treatment.

202 the leg has been recommended to prevent the recurrence of cellulitis, but there is limited evidence

203 taV each did not differ significantly across recurrence of DH (P >= .92) or between DH events with an

204 Some patients have recurrence of flares, or become antibiotic-dependent, an

205 abdominal pain recurrence), the presence and recurrence of gastrointestinal symptoms and the length o

206 ts and the EGFR inhibitors, which results in recurrence of highly aggressive lung tumors.

207 No patient showed recurrence of inflammation after cessation of brimonidin

208 eral strategies may be useful to prevent the recurrence of kidney stones.

209 Nonprimary infections due to recurrence of latent infections or reinfection with new

210 e to these therapies leads to systemic tumor recurrence of metastatic disease.

211 The primary endpoint was a recurrence of negative remodeling, defined as an increas

212 this longitudinal study was to evaluate the recurrence of periodontal disease in obese and normal we

213 adjuvants to oral hygiene procedures on the recurrence of periodontitis (RP) during periodontal main

214 ter PPV, BCVA had increased to 20/32 without recurrence of RD and no evidence of tumor activity.

215 DI exist, they are either expensive or cause recurrence of the infection due to their altering the co

216 us parental species, a common pattern is the recurrence of the same phenotypic polymorphism in many s

217 Recurrence of toxinogenic CD was observed in 9 children,

218 Thus, recurrence of UTIs and associated bladder dysfunction ar

219 Recurrences of zoster ophthalmicus are uncommon because

220 The level of suspicion for recurrence on (11)C-choline PET/CT was scored (0, negati

221 tify driver genes on the basis of mutational recurrence or approximate the functional consequences of

222 n rationale that cUTIs have a higher risk of recurrence or chronification, progression or severe outc

223 (the time between randomisation and distant recurrence or death before recurrence), an exploratory e

224 Tamoxifen- treated patients with recurrence or non-recurrence were selected using a match

225 a-PSMA-11 did not differ (P > 0.05) in local recurrence or primary prostate cancer; however, the tumo

226 ly and serve as reservoirs to drive relapse, recurrence or progression to more aggressive forms.

227 5) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity.

228 n expression was not associated with risk of recurrence or with SPP1-gene expression, suggesting SPP1

229 rating genomic data was highly predictive of recurrence (OR 13.20, P = 0.0197).

230 sis of baseline characteristics and 3259 for recurrence outcomes.

231 atients had (11)C-choline-positive suspected recurrences outside the initial treatment field.

232 PRKD1 expression correlated with metastatic recurrence, particularly in basal breast cancer.

233 To reduce the risk of recurrence, patients should consume a high-quality diet,

234 wn if there are sex-based differences in HCC recurrence post-liver transplant.

235 ll recurrence, multiple recurrence, advanced recurrence, proximal recurrence, and distal adenoma recu

236 Cross Recurrence Quantification Analysis was applied to obtain

237 The difference in the recurrence rate between group I (29.4%) and group II (11

238 for efficacy in reducing the historical 18% recurrence rate of CHB.

239 The pooled overall recurrence rate was 43% (95%CI: 33%-53%) over a mean fol

240 hich leads to fast disease progression, high recurrence rate, and short survival.

241 ly, there exist no data on second-generation recurrence rates among families affected by ASD.

242 Since recurrence rates are higher and disease-free survival is

243 rm but is regularly required due to the high recurrence rates of nosocomial antibiotic-associated dia

244 plain the basis for the extraordinarily high recurrence rates of UTIs, we examined adaptive immune re

245 exist, enabling the creation of an empirical recurrence rates ratio (ERRR), a smoothing statistic tha

246 Recurrence rates were significantly different (4.0% for

247 s), including determination of incidence and recurrence rates, is of integral importance in cancer im

248 cleritis were assessed, as well as scleritis recurrence rates, treatment, and complications.

249 Complications included recurrence, re-operation, and mesh complications.

250 Outcomes were recurrence/relapse rate of any mood episode (RR-any, pri

251 nitial hope that their presence would inform recurrence risk and thus decisions on anticoagulation du

252 The recurrence risk for autism spectrum disorders is substan

253 tus was associated with significantly higher recurrence risk in subgroups within Metroticket 2.0 crit

254 The 9-year locoregional recurrence risk was low.

255 ositive/HER2-negative breast cancer and high recurrence risk, as defined by clinicopathologic charact

256 to be the most important determinant of VTE recurrence risk.

257 tamoxifen alone is minimal for those at low recurrence risk.

258 adjuvant chemotherapy is indicated to reduce recurrence risk.

259 alized care and counselling on prognosis and recurrence risk.

260 fined by the continuous composite measure of recurrence risk.

261 sis using a random effects model assessed AF recurrence stratified by DAT <=1 year versus >1 year.

262 The high incidence of recurrence suggests the need for new treatments to preve

263 tly lower rates of post-liver transplant HCC recurrence than men (4.0 v.

264 ed, symptomatic recurrence from radiographic recurrence (that is, with radiographic evidence of a new

265 s), feasibility (evaluated by abdominal pain recurrence), the presence and recurrence of gastrointest

266 For participants with postresection local recurrence, the median OS was 16 months from diagnosis o

267 To reduce the risk of hernia recurrence, the optimal timing of elective repair is aft

268 remained significantly associated with early recurrence; this association remained true when analyzed

269 When analysing fixation guidance without recurrence to objects, visual salience predicted whether

270 receive education on anaphylaxis and risk of recurrence, trigger avoidance, self-injectable epinephri

271 d in 159/511 patients (31%) with symptomatic recurrence versus 77/159 (48%) asymptomatic patients (P

272 etween ctHPVDNA positivity and biopsy-proven recurrence was 3.9 months (range, 0.37-12.9 months).

273 At a mean of 12.8 months, freedom from VT recurrence was 67% in the overall cohort.

274 HSIL recurrence was associated with a LEEP biopsy result of H

275 The incidence of a local recurrence was comparable (13% vs. 15% at 10 years; P =

276 Tumor recurrence was defined as biopsy-proven vital tumor at t

277 The pattern of recurrence was DM in 81.9% of patients, versus LR in 11.

278 In patients outside UCSF, tumor recurrence was equivalent to Milan and UCSF criteria rec

279 Tumor recurrence was histology-confirmed in 40% (28/70) of pat

280 of 11 years (range 1 mo-25 yrs), symptomatic recurrence was observed in 61%: 15 patients at the SSIS

281 In univariate analysis, rate of recurrence was reduced when extended initial surgery had

282 Tumor recurrence was significantly less common in pN0 patients

283 Recurrence was similar in patients receiving PMRT compar

284 ier estimates of 8-year freedom from distant recurrence were analyzed using subpopulation treatment e

285 s hypo/hyperpigmentation, skin infection, or recurrence were reported.

286 fen- treated patients with recurrence or non-recurrence were selected using a matched case-control de

287 VT recurrences were documented in 25 patients (20%) by 12 m

288 ensity score matching analysis, 7/159 (4.4%) recurrences were noted in the open RH group and 18/156 (

289 advanced pancreatic cancer and 10 with local recurrence) were included.

290 isease-specific mortality (DSM), and time-to-recurrence, were reported.

291 uberculosis (TB) disease, TB morality and TB recurrence, when being treated with metformin.

292 pair was not associated with reoperation for recurrence, while a subsequent pregnancy was associated

293 before prostatectomy and 38 with biochemical recurrence) who underwent (68)Ga-PSMA-11 PET/MRI or PET/

294 on with clinical characteristics and time-to-recurrence with a 3 month blanking period.

295 ow that SpAn predicts the 5-year risk of CRC recurrence with a mean AUROC of 88.5% (SE of 0.1%), sign

296 nificantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with

297 e improvement in 8-year freedom from distant recurrence with exemestane plus OFS versus tamoxifen plu

298 nce, proximal recurrence, and distal adenoma recurrence with odds ratios of 4.32 (2.06-9.04 95% CI),

299 Nine of them (90%) experienced HCC recurrence within 1 year, supporting vh-DNA as an indepe

300 transplantation is an efficient treatment of recurrences within criteria.